Echo-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy
Authors:
- I. V. PershukovIPI. V. Pershukov
- B. A. AkbalaevaBAB. A. Akbalaeva
- L. V. ShulzhenkoLSL. V. Shulzhenko
- T. A. BatyralievTBT. A. Batyraliev
- O. V. GurovichOGO. V. Gurovich
- V. V. VinogradskaiaVVV. V. Vinogradskaia
- Z. A. KarbenZKZ. A. Karben
- D. V. FettserDFD. V. Fettser
- T. N. KuznetsovaTKT. N. Kuznetsova
- E. Yu. IvanenkovaEIE. Yu. Ivanenkova
- N. Raiimbek UuluNUN. Raiimbek Uulu
- M. V. KvasovaMKM. V. Kvasova
Open Access
- 10 June 2024
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (6) , 4038
Abstract
Aim. To assess the incidence and timing of subclinical cardiac dysfunction associated with therapy for HER2-positive locally advanced or metastatic breast cancer, and to analyze the difference in time from significant reduction in left ventricular (LV) global longitudinal strain (GLS) to significant reduction in LV ejection fraction (LVEF) (cardiotoxicity "echo-loop").Material and methods. A total of 187 women 58±11 years without baseline cardiac dysfunction with verified HER2-positive locally advanced or metastatic breast cancer who received sequential adjuvant therapy with doxorubicin+cyclophosphamide, docetaxel+trastuzumab and trastuzumab monotherapy were followed up in 4 centers in four countries within 12 months with regular (every 3 weeks) speckle-tracking echocardiographic monitoring.Results. Subclinical cardiac dysfunction associated with breast cancer therapy (CTRCD) appears in each block of therapy after the first course. Its frequency increases significantly after each subsequent course compared to the previous one. By the end of the 4th course in each block of therapy, subclinical CTRCD is noted from 24,6% (almost every 4th patient in the chemotherapy block) to 32,6-33,7% (almost every 3rd patient in the chemotherapy and targeted therapy blocks). In 24 out of 25 cases of severe subclinical CTRCD (96%) with a fall in LVEF 15% was preceded. The time difference from a decrease in LV GLS to a decrease in LVEF Conclusion. Until recently, the period of identified moderate subclinical cardiac dysfunction was not used to prescribe therapy for the prevention and treatment of cardiotoxicity. Enhanced speckle-tracking echocardiographic monitoring may reduce the incidence of severe subclinical and overt clinical cardiac dysfunction. Guidelines for cardiotoxicity monitoring should be reviewed to reduce the incidence of severe cardiac complications of cancer therapy.Keywords
This publication has 14 references indexed in Scilit:
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- Role of Speckle Tracking Echocardiography in the Evaluation of Breast Cancer Patients Undergoing Chemotherapy: Review and Meta-analysis of the LiteratureCardiovascular Toxicology, 2019
- Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicityEuropean Heart Journal - Cardiovascular Imaging, 2017
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood CancerJACC, 2015
- Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2014
- The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma PatientsJACC: Heart Failure, 2013
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Screening Adult Survivors of Childhood Cancer for Cardiomyopathy: Comparison of Echocardiography and Cardiac Magnetic Resonance ImagingJournal of Clinical Oncology, 2012
- Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive ReviewProgress in Cardiovascular Diseases, 2010